Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Development of Nano-Carriers for Leishmania Vaccine Delivery Publisher Pubmed



Askarizadeh A1 ; Badiee A1, 2 ; Khamesipour A3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Nanotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
  2. 2. Department of Pharmaceutical Nanotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
  3. 3. Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, Tehran, Iran

Source: Expert Opinion on Drug Delivery Published:2020


Abstract

Introduction: Leishmaniasis is a neglected tropical infection caused by several species of intracellular protozoan parasites of the genus Leishmania. It is strongly believed that the development of vaccines is the most appropriate approach to control leishmaniasis. However, there is no vaccine available yet and the lack of an appropriate adjuvant delivery system is the main reason. Areas covered: Adjuvants are the utmost important part of a vaccine, to induce the immune response in the right direction. Limitations and drawbacks of conventional adjuvants have been necessitated the development of novel particulate delivery systems as adjuvants to obtain desirable protection against infectious diseases such as leishmaniasis. This review focused on particulate adjuvants especially nanoparticles that are in use to develop vaccines against leishmaniasis. The list of adjuvants includes generally lipids-, polymers-, or mineral-based delivery systems that target antigens specifically to the site of action within the host’s body and enhance immune responses. Expert opinion: Over the past few years, there has been an increasing interest in developing particulate adjuvants as alternatives to immunostimulatory types. The composition of nano-carriers and particularly the physicochemical properties of nanoparticles have great potential to overcome challenges posed to leishmaniasis vaccine developments. © 2020, © 2020 Informa UK Limited, trading as Taylor & Francis Group.
Related Docs
View other Related Docs
1. Delivery Systems for Leishmania Vaccine Development, Expert Review of Vaccines (2016)
2. The Role of Lpd-Nanoparticles Containing Recombinant Major Surface Glycoprotein of Leishmania (Rgp63) in Protection Against Leishmaniasis in Murine Model, Immunopharmacology and Immunotoxicology (2018)
3. The Role of Mpl and Imiquimod Adjuvants in Enhancement of Immune Response and Protection in Balb/C Mice Immunized With Soluble Leishmania Antigen (Sla) Encapsulated in Nanoliposome, Artificial Cells# Nanomedicine and Biotechnology (2018)
4. Evaluation of Immune Response Against Leishmaniasis in Balb/C Mice Immunized With Cationic Dotap/Dope/Chol Liposomes Containing Soluble Leishmania Major Antigens, Iranian Journal of Parasitology (2019)
5. Coadminstration of L. Major Amastigote Class I Nuclease (Rlmacin) With Lpd Nanoparticles Delays the Progression of Skin Lesion and the L. Major Dissemination to the Spleen in Balb/C Mice-Based Experimental Setting, Acta Tropica (2016)
6. Multi-Antigen Vaccination With Lpd Nanoparticles Containing Rgp63 and Rlmac1n Proteins Induced Effective Immune Response Against Leishmaniasis in Animal Model, Journal of Drug Delivery Science and Technology (2021)
7. Cationic Liposomes Formulated With a Novel Whole Leishmania Lysate (Wll) As a Vaccine for Leishmaniasis in Murine Model, Immunobiology (2018)
8. Cationic Immune Stimulating Complexes Containing Soluble Leishmania Antigens: Preparation, Characterization and in Vivo Immune Response Evaluation, Iranian Journal of Immunology (2015)
Experts (# of related papers)
View all Related Experts
Mahdi Mohebali (6)
Mohammad Ali Nilforoushzadeh (3)
Other Related Docs
9. A Phospholipase-A Activity in Soluble Leishmania Antigens Causes Instability of Liposomes, Current Drug Delivery (2020)
10. Immunization Against Cutaneous Leishmaniasis by Alginate Microspheres Loaded With Autoclaved Leishmania Major (Alm) and Quillaja Saponins, Iranian Journal of Pharmaceutical Research (2016)
11. Pegylation of Cationic Liposomes Encapsulating Soluble Leishmania Antigens Reduces the Adjuvant Efficacy of Liposomes in Murine Model, Parasite Immunology (2017)
12. Sphingomyelin Liposome Bearing Whole Leishmania Lysate Antigens Induce Strong Th2 Immune Response in Balb/C Mice, Iranian Journal of Basic Medical Sciences (2021)
13. Combinatorial Delivery of Antigen and Tlr Agonists Via Plga Nanoparticles Modulates Leishmania Major-Infected-Macrophages Activation, Biomedicine and Pharmacotherapy (2021)
14. Immunization Against Leishmania Major Infection in Balb/C Mice Using a Subunit-Based Dna Vaccine Derived From Tsa, Lmsti1, Kmp11, and Lack Predominant Antigens, Iranian Journal of Basic Medical Sciences (2019)
15. The Role of Iscomatrix Bilayer Composition to Induce a Cell Mediated Immunity and Protection Against Leishmaniasis in Balb/C Mice, Iranian Journal of Basic Medical Sciences (2016)
16. Double-Blind Randomized Efficacy Field Trial of Alum Precipitated Autoclaved Leishmania Major (Alum-Alm) Vaccine Mixed With Bcg Plus Imiquimod Vs. Placebo Control Group, Iranian Journal of Parasitology (2015)
17. P435 Her2/Neu-Derived Peptide Conjugated to Liposomes Containing Dope As an Effective Prophylactic Vaccine Formulation for Breast Cancer, Artificial Cells# Nanomedicine and Biotechnology (2019)
18. In-Vitro and In-Vivo Comparison of Rsag1-Loaded Plga Prepared by Encapsulation and Adsorption Methods As an Efficient Vaccine Against Toxoplasma Gondii”, Journal of Drug Delivery Science and Technology (2020)
19. A State-Of-The-Art Review on Solid Lipid Nanoparticles As a Nanovaccines Delivery System, Journal of Drug Delivery Science and Technology (2023)
20. An Alphavirus-Derived Self-Amplifying Mrna Encoding Ppsp15-Lmsti1 Fusion Protein for the Design of a Vaccine Against Leishmaniasis, Parasitology International (2022)
21. Preparation of Nanoliposomes Containing Her2/Neu (P5+435) Peptide and Evaluation of Their Immune Responses and Anti-Tumoral Effects As a Prophylactic Vaccine Against Breast Cancer, PLoS ONE (2020)
22. Vaccines for Preventing Cutaneous Leishmaniasis, Cochrane Database of Systematic Reviews (2018)
23. Engineering and Design of Promising T-Cell-Based Multi-Epitope Vaccine Candidates Against Leishmaniasis, Scientific Reports (2023)
24. A Nano-Liposome Vaccine Carrying E75, a Her-2/Neu-Derived Peptide, Exhibits Significant Antitumour Activity in Mice, Journal of Drug Targeting (2018)
25. Potential Biomarkers of Immune Protection in Human Leishmaniasis, Medical Microbiology and Immunology (2021)
26. Synergistic Effect of Rsag1 and Rgra2 Antigens Formulated in Plga Microspheres in Eliciting Immune Protection Against Toxoplasama Gondii, Experimental Parasitology (2016)
27. An Overview of Leishmanization Experience: A Successful Control Measure and a Tool to Evaluate Candidate Vaccines, Acta Tropica (2019)
28. Evolution of Antigen-Specific Immune Responses in Cutaneous Leishmaniasis Patients, Parasite Immunology (2021)
29. Induction of Immune Responses by Dna Vaccines Formulated With Dendrimer and Poly (Methyl Methacrylate) (Pmma) Nano-Adjuvants in Balb/C Mice Infected With Leishmania Major, Open Access Macedonian Journal of Medical Sciences (2018)
30. Conjugated Nanoliposome With the Her2/ Neu-Derived Peptide Gp2 As an Effective Vaccine Against Breast Cancer in Mice Xenograft Model, PLoS ONE (2017)
31. Nanoliposomes Carrying Her2/Neu-Derived Peptide Ae36 With Cpg-Odn Exhibit Therapeutic and Prophylactic Activities in a Mice Tubo Model of Breast Cancer, Immunology Letters (2017)
32. Commensal and Pathogenic Bacterial-Derived Extracellular Vesicles in Host-Bacterial and Interbacterial Dialogues: Two Sides of the Same Coin, Journal of Immunology Research (2022)
33. Human Neutrophil Peptide 1 As Immunotherapeutic Agent Against Leishmania Infected Balb/C Mice, PLoS Neglected Tropical Diseases (2017)
34. Emerging Role of Microbiota Derived Outer Membrane Vesicles to Preventive, Therapeutic and Diagnostic Proposes, Infectious Agents and Cancer (2023)
35. Novel Strategies and Pharmaceutical Agents for the Treatment of Leish-Maniasis: A Review, Anti-Infective Agents (2020)
36. An Immunoproteomic Approach to Identifying Immunoreactive Proteins in Leishmania Infantum Amastigotes Using Sera of Dogs Infected With Canine Visceral Leishmaniasis, Pathogens and Global Health (2019)
37. Liposomes: Structure, Biomedical Applications, and Stability Parameters With Emphasis on Cholesterol, Frontiers in Bioengineering and Biotechnology (2021)
38. Development of a New Live Attenuated Leishmania Major P27 Gene Knockout: Safety and Immunogenicity Evaluation in Balb/C Mice, Cellular Immunology (2018)
39. Evaluation of a Novel Lentiviral Vaccine Expressing Kmp11-Haspb Fusion Protein Against Leishmania Infantum in Balb/C Mice, Parasite Immunology (2016)
40. Engineering the Niche for Hair Regeneration — a Critical Review, Nanomedicine: Nanotechnology# Biology# and Medicine (2019)
41. Antileishmanial Activity of Urtica Dioica Extract Against Zoonotic Cutaneous Leishmaniasis, PLoS Neglected Tropical Diseases (2020)
42. Polymeric Nanoparticles for Dna Vaccine-Based Cancer Immunotherapy: A Review, Biotechnology Letters (2023)
43. Effects of Combined Therapy With Silymarin and Glucantime on Leishmaniasis Induced by Leishmania Major in Balb/C Mice, Drug Research (2015)
44. Demographic and Clinical Characteristics of Children With Cutaneous Leishmaniasis in Isfahan Province, Iran, During 2011-2015, Journal of Isfahan Medical School (2017)
45. Nanoimmunoengineering Strategies in Cancer Diagnosis and Therapy, Clinical and Translational Oncology (2023)
46. Self-Assembled Peptide/Polymer Hybrid Nanoplatform for Cancer Immunostimulating Therapies, Drug Delivery and Translational Research (2024)
47. Sambucus Ebulus Extract Stimulates Cellular Responses in Cutaneous Leishmaniasis, Parasite Immunology (2019)
48. Green Synthesis of Iron Oxide Nanoparticles by Extract of Eriobotrya Japonica Leaves: Comparing the Characteristics by Pegylated Method and Conventional Chemical Method, Nanomedicine Research Journal (2024)
49. Effects of Amphotericin B-Conjugated Functionalized Carbon Nanoparticles in the Treatment of Cutaneous Leishmaniasis, Parasite Immunology (2024)
50. A Comprehensive Review of Cutaneous Leishmaniasis in Kerman Province, Southeastern Iran- Narrative Review Article, Iranian Journal of Public Health (2015)